NeoGenomics (NASDAQ:NEO) Rating Reiterated by Benchmark

Benchmark restated their buy rating on shares of NeoGenomics (NASDAQ:NEO) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $18.00 price objective on the medical research company’s stock.

A number of other equities analysts have also recently weighed in on NEO. Stephens restated an overweight rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Needham & Company LLC restated a buy rating and issued a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $19.89.

NeoGenomics Stock Down 1.0 %

Shares of NASDAQ:NEO opened at $14.50 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01. NeoGenomics has a 1 year low of $11.03 and a 1 year high of $21.22. The stock has a market capitalization of $1.85 billion, a P/E ratio of -22.27 and a beta of 1.19. The stock has a 50-day simple moving average of $16.06 and a 200-day simple moving average of $14.94.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The business had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same quarter in the previous year, the business earned ($0.09) EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. Equities analysts forecast that NeoGenomics will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On NeoGenomics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Arizona State Retirement System raised its position in shares of NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 708 shares in the last quarter. Crossmark Global Holdings Inc. raised its position in shares of NeoGenomics by 2.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 842 shares in the last quarter. Banque Cantonale Vaudoise increased its position in NeoGenomics by 6.6% in the first quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after buying an additional 993 shares during the period. Oppenheimer Asset Management Inc. increased its position in NeoGenomics by 3.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock worth $451,000 after buying an additional 1,030 shares during the period. Finally, Louisiana State Employees Retirement System increased its position in NeoGenomics by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 64,300 shares of the medical research company’s stock worth $892,000 after buying an additional 1,200 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.